-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK’s efimosfermin wins FDA Breakthrough Therapy tag for MASH

PUBT·04/27/2026 12:14:55
Listen to the news
GSK’s efimosfermin wins FDA Breakthrough Therapy tag for MASH
  • GSK won FDA Breakthrough Therapy designation for efimosfermin to treat metabolic dysfunction-associated steatohepatitis (MASH).
  • EMA granted PRIME designation for efimosfermin in MASH.
  • Designations were backed by Phase II data showing improved liver fibrosis at 48 weeks in F2/F3 patients.
  • Efimosfermin is in Phase III ZENITH-1 and ZENITH-2 trials in F2/F3 MASH.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-003947), on April 27, 2026, and is solely responsible for the information contained therein.